Valeant Board Tells CEO To Cooperate With Senators
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals International Inc.'s board on April 11 took an unusual move in declaring it had asked the company's soon-to-be-exiting CEO Michael Pearson to cooperate with the US Senate Committee on Aging's subpoena for a deposition.